Well Referenced

Tag: PDE5 inhibitors

Treatment of Diabetic Impotence with Umbilical Cord Blood Stem Cell Intracavernosal Transplant: Preliminary Report of 7 Cases

This 2010 pilot study assessed the safety and efficacy of intracavernosal injections of human umbilical cord blood stem cells (hUCBSCs) in seven male patients (ages 57–87) with type 2 diabetes mellitus and refractory erectile dysfunction (ED). Each patient received a single injection of 1.5×10⁷ hUCBSCs without immunosuppression. Over a 9-month

Read More »
June 26, 2025 No Comments

Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin®) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series

This 2022 case series evaluated the safety and efficacy of intracavernosal injection (ICI) of incobotulinumtoxinA (Xeomin®) 100 U as an adjunct to standard pharmacological treatments (PDE5 inhibitors or PGE1 ICIs) in 66 men with difficult-to-treat erectile dysfunction (ED). Approximately 52% of patients achieved a clinically meaningful improvement in International Index

Read More »
June 26, 2025 No Comments

The Efficacy of Li-ESWT Combined With VED in Diabetic ED Patients Unresponsive to PDE5is: A Single-Center, Randomized Clinical Trial

This 2022 randomized clinical trial assessed the efficacy of combining low-intensity extracorporeal shock wave therapy (Li-ESWT) with vacuum erectile device (VED) therapy in 105 diabetic men with erectile dysfunction (ED) unresponsive to phosphodiesterase type 5 inhibitors (PDE5is). Participants were divided into three groups: VED alone, Li-ESWT alone, and combined VED

Read More »
June 26, 2025 No Comments

Low Intensity Shockwave Therapy in Combination with Phosphodiesterase-5 Inhibitors is an Effective and Safe Treatment Option in Patients with Vasculogenic ED who are PDE5i Non-responders: A Multicenter Single-arm Clinical Trial

This 2021 multicenter, open-label prospective study evaluated the safety and efficacy of combining low-intensity extracorporeal shockwave therapy (Li-ESWT) with phosphodiesterase-5 inhibitors (PDE5i) in 109 men with vasculogenic erectile dysfunction (ED) unresponsive to PDE5i monotherapy. Li-ESWT was administered twice weekly for 3 weeks, delivering 3,000 shockwaves per session at 0.25 mJ/mm²

Read More »
June 26, 2025 No Comments

Erectile Dysfunction: Treatments, Advances and New Therapeutic Strategies

This 2023 review outlines current and emerging treatments for erectile dysfunction (ED), affecting approximately 40% of men aged 40–70. First-line therapies include oral phosphodiesterase type 5 inhibitors (PDE5i) such as sildenafil and tadalafil, and intracavernosal injections of agents like prostaglandin E1. Experimental pharmacotherapies under investigation include dopamine D₄ receptor agonists,

Read More »
June 26, 2025 No Comments

Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies

This integrated analysis evaluated the efficacy and safety of once-daily tadalafil at doses of 2.5 mg and 5 mg over 12 weeks in 1,913 men with erectile dysfunction (ED) across various subpopulations, including different ages, ethnicities, comorbidities, and ED characteristics. Both tadalafil doses significantly improved erectile function compared to placebo,

Read More »
June 26, 2025 No Comments

The future is today: emerging drugs for the treatment of erectile dysfunction

This review explores emerging drug therapies for erectile dysfunction (ED), discussing both central regulators (clavulanic acid, dopamine and melanocortin receptor agonists) and peripheral regulators (novel PDE5 inhibitors, soluble and particulate guanylyl cyclase activators, rho-kinase inhibitors, and maxi-K channel openers). These emerging treatments offer the potential for individualized approaches tailored to

Read More »
June 26, 2025 No Comments

The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction

This randomized controlled trial examined the effects of combining testosterone and vardenafil (a PDE5 inhibitor) on cognitive, affective, and physiological sexual functions in 28 women with sexual dysfunction. The study found that in women with low initial attention to sexual cues, testosterone increased sensitivity to these cues, and the combination

Read More »
June 26, 2025 No Comments

Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily

This randomized controlled trial investigated the treatment satisfaction of men with erectile dysfunction (ED) and their partners after switching from on-demand phosphodiesterase type 5 (PDE5) inhibitors to a daily regimen of tadalafil 5 mg. The study included men aged 18 and older with a history of ED who had been

Read More »
June 26, 2025 No Comments